Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have Type 2 Diabetes (T2DM) with HbA1c ≥7% to ≤10% at screening, on stable therapy for the last 3 months prior to screening. T2DM may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling) EXCEPT dipeptidyl peptidase 4 (DPP-4) inhibitors or glucagon like peptide-1 receptor agonists (GLP-1 RAs)~* Have a BMI of ≥27 kg/m²~* Are overweight or have obesity~* Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight~* Are at least 18 years of age and age of majority per local laws and regulations~Exclusion Criteria:~* Have Type 1 diabetes mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except T2DM~* Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values \>270 mg/dL(on 2 nonconsecutive days) prior to Visit 3~* Have proliferative diabetic retinopathy OR diabetic macular edema OR non-proliferative diabetic retinopathy that requires acute treatment~* Have self-reported change in body weight \>5kg within 3 months prior to screening~* Have had a history of chronic or acute pancreatitis~* Change in body weight greater than 5 kg within 3 months prior to starting study~* Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity~* Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)~* History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years~* Any lifetime history of a suicide attempt

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 10 milligrams (mg) Tirzepatide (Type: EXPERIMENTAL): 10 mg Tirzepatide administered subcutaneously (SC) once weekly (QW)
- 15 mg Tirzepatide (Type: EXPERIMENTAL): 15 mg Tirzepatide administered SC QW
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered SC QW

Based on this trial design, predict the completion outcome and termination type (if applicable).